Barinthus Biotherapeutics plc
BRNS
$1.20
$0.0151.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 4,381.74% | 1,766.46% | 106.21% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 4,381.74% | 1,766.46% | 106.21% | -100.00% |
| Cost of Revenue | -24.21% | -23.26% | 13.24% | -44.11% | -65.72% |
| Gross Profit | 159.00% | 153.54% | 134.26% | 118.59% | 41.48% |
| SG&A Expenses | 36.46% | -10.91% | -40.67% | -13.15% | -18.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 25.09% | -19,900.00% | -- | -- | -- |
| Total Operating Expenses | 0.94% | -15.88% | -25.29% | -17.80% | -12.70% |
| Operating Income | 20.84% | 34.98% | 43.10% | 28.12% | -5.25% |
| Income Before Tax | -6.46% | 10.89% | 19.99% | 28.00% | -10.11% |
| Income Tax Expenses | 96.80% | 98.88% | 98.57% | 79.71% | 66.24% |
| Earnings from Continuing Operations | -8.83% | 7.67% | 16.70% | 25.14% | -16.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 0.00% | 9.00% | -28.57% | 30.00% |
| Net Income | -8.84% | 7.68% | 16.73% | 25.14% | -16.12% |
| EBIT | 20.84% | 34.98% | 43.10% | 28.12% | -5.25% |
| EBITDA | 23.38% | 37.15% | 44.79% | 29.52% | -3.94% |
| EPS Basic | -5.00% | 10.56% | 18.88% | 26.76% | -14.03% |
| Normalized Basic EPS | 24.39% | 37.65% | 44.88% | 29.96% | -7.49% |
| EPS Diluted | -4.91% | 10.60% | 19.01% | 26.67% | -14.27% |
| Normalized Diluted EPS | 24.39% | 37.65% | 44.88% | 29.96% | -7.15% |
| Average Basic Shares Outstanding | 3.39% | 2.97% | 2.51% | 2.31% | 2.59% |
| Average Diluted Shares Outstanding | 3.39% | 2.97% | 2.51% | 2.31% | 1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |